Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Audeo Oncology's Total Stockholders Equity for the quarter that ended in Sep. 2012 was $2.06 Mil. Audeo Oncology's Total Assets for the quarter that ended in Sep. 2012 was $7.81 Mil.
Therefore, Audeo Oncology's Equity to Asset Ratio for the quarter that ended in Sep. 2012 was 0.26.
The historical rank and industry rank for Audeo Oncology's Equity-to-Asset or its related term are showing as below:
AURX's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.59 * Ranked among companies with meaningful Equity-to-Asset only.
Audeo Oncology Equity-to-Asset Historical Data
The historical data trend for Audeo Oncology's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Audeo Oncology Equity-to-Asset Chart
Audeo Oncology Annual Data
Trend
Jun10
Jun11
Jun12
Equity-to-Asset
-98.38
-24.25
0.72
Audeo Oncology Quarterly Data
Jun11
Mar12
Jun12
Sep12
Equity-to-Asset
-24.25
-17.72
0.72
0.26
Competitive Comparison of Audeo Oncology's Equity-to-Asset
For the Drug Manufacturers - General subindustry, Audeo Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Audeo Oncology's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Audeo Oncology's Equity-to-Asset falls into.
Audeo Oncology Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Audeo Oncology's Equity to Asset Ratio for the fiscal year that ended in Jun. 2012 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Audeo Oncology Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Audeo Oncology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Audeo Oncology (Audeo Oncology) Business Description
Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DELISTED:AURX has been successfully added to your